Deborah M. Messemer - 10 Jun 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Reporting relationship: Director
Issuer ticker: ALLO
Reported as of: 10 Jun 2025
Net transaction value: -$52,377
SEC form: 4
Accepted by SEC: 12 Jun 2025, 16:18:31 UTC
Prior SEC filing: 06 Jun 2025
Next SEC filing: 23 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/Earl Douglas, Attorney-in-Fact

Key filing fact

Deborah M. Messemer filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 12 Jun 2025.

Key facts

This page summarizes Deborah M. Messemer's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Jun 2025, 16:18.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: -$52,377.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001754424 Primary reporting owner

MESSEMER DEBORAH M.

Relationship: Director
Address: 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Signature: /s/Earl Douglas, Attorney-in-Fact
Signature date: 12 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALLO transaction

Common Stock

Sale

Transaction value: $52,377
Shares: -36,885
Change %: -26%
Price: $1.42
Shares after: 107,431
Date: 10 Jun 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 8/30/2024.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.38 to $1.445, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.